Mutants separately resistant to novobiocin, coumermycin, nalidixic acid, and oxolinic acid contained gyrase activity as measured in vitro that was resistant to the antibiotics, indicating that the mutations represented structural alterations of the enzyme. One Novr mutant contained an altered B subunit of the enzyme, as judged by the ability of a plasmid, pNovl, containing the mutation to complement a temperature-sensitive gyrase B mutation in Escherichia coli and to cause novobiocin resistance in that strain. Three other Novr mutations did not confer antibiotic resistance to the gyrase but appeared to increase the amount of active enzyme in the cell. One of these, novBI, could only act in cis, whereas a new mutation, novC, could act in trans. An RNA polymerase mutation partially substituted for the novBI mutation, suggesting that novBI may be a mutation in a promoter region for the B subunit gene. Growth responses of strains containing various combinations of mutations on plasmids or on the chromosome indicated that low-level resistance to novobiocin or coumermycin may have resulted from multiple copies of wild-type genes coding for the gyrase B subunit, whereas high-level resistance required a structural change in the gyrase B gene and was also dependent on alteration in a regulatory region. When there was mismatch at the novB locus, with the novBl mutation either on a plasmid or the chrotnosome, and the corresponding wild-type gene present in trans, chromosome to plasmid recombination during transformation was much higher than when the genes matched, probably because plasmid to chromosome recombination, eliminating the plasmid, was inhibited by the mismatch.
Mutants separately resistant to novobiocin, coumermycin, nalidixic acid, and oxolinic acid contained gyrase activity as measured in vitro that was resistant to the antibiotics, indicating that the mutations represented structural alterations of the enzyme. One Novr mutant contained an altered B subunit of the enzyme, as judged by the ability of a plasmid, pNovl, containing the mutation to complement a temperature-sensitive gyrase B mutation in Escherichia coli and to cause novobiocin resistance in that strain. Three other Novr mutations did not confer antibiotic resistance to the gyrase but appeared to increase the amount of active enzyme in the cell. One of these, novBI, could only act in cis, whereas a new mutation, novC, could act in trans. An RNA polymerase mutation partially substituted for the novBI mutation, suggesting that novBI may be a mutation in a promoter region for the B subunit gene. Growth responses of strains containing various combinations of mutations on plasmids or on the chromosome indicated that low-level resistance to novobiocin or coumermycin may have resulted from multiple copies of wild-type genes coding for the gyrase B subunit, whereas high-level resistance required a structural change in the gyrase B gene and was also dependent on alteration in a regulatory region. When there was mismatch at the novB locus, with the novBl mutation either on a plasmid or the chrotnosome, and the corresponding wild-type gene present in trans, chromosome to plasmid recombination during transformation was much higher than when the genes matched, probably because plasmid to chromosome recombination, eliminating the plasmid, was inhibited by the mismatch.
In previous studies, we investigated the transformation of a plasmid conferring novobiocin resistance on its host and the ability of the plasmid to acquire genetic information from the recipient chromosome (17) (18) (19) . The plasmid pNovl, shown to code for the novobiocin-resistant gyrase (19) , was constructed by ligating a piece of chromosomal DNA from a novobiocin-resistant strain (derived from Haemophilus influenzae Rd) to the plasmid RSF0885 (18) . The homology between the plasmid with the chromosomal insert and the chromosome enables pNovl entering a competent cell to become established in a wild-type, but not a rec-J or rec-2 mutant, recipient several orders of magnitude more efficiently than does the parent plasmid RSF0885 without the chromosomal insert (18) . On entering the cell the plasmid pNovl frequently recombines with the wild-type, but not the rec-J or rec-2, chromosome to becomfe converted to pNovls, coding for a novobiocin-sensitive gyrase (17, 19) .
The novobiocin resistance of pNovl is caused by two tightly linked mutations, which we designated novAl and novBl. The two mutations together confer resistance to a concentration of 25 jxg of novobiocin per ml, and novAl and novBI individually cause resistance to 2.5 and 1.0 ,ug/ml, respectively. In this study we separated these mutations by a method similar to that used previously (4) and cloned them individually. We show here that the novAl mutation caused changes in the gyrase B subunit, but the novBI mutation did not affect the novobiocin sensitivity of the gyrase, as measured by in vitro assay.
We collected a large number of mutations which map Menzel. Transformation. H. influenzae was transformed as de- Rd derivatives  JKS1  JKS2  JKS3  JKS4  JKS5  JKS6  JKS7  JKS8  JKS9  JKS10  JKS11  JKS12  JkS13  JKS14  JKS15   JKS16  WLA5  WLA5-1   WLA5-2  WLA5-3   WLA5-4  WLA5-5   JKS17  JKS18  JKS19  JKS20   JKS21  JKS22  JKS23  JKS24  JKS25  JKS26   BC200   BC200 derivatives   JKS27   JKS28   JKS29  JKS30  JKS31  JKS32  JKS33 through  JKS40   JKS41   JKS42   JKS43  JKS44  JKS45   strA  novAl  novA3  novBl  novA1 novBI  halAl  nalA2   couA6  couA8  rifAl  rifA2  rifA2 couA8  rifA3 rec-l (20) . E. coli transformation was by the CaCl2 method as presented by Schleif and Wensink (13) .
Isolation of strains cobtaining only the novB1 resistance marker. In accordance with the method of Day and Rupert (4) , Rd strA novB1 was isolated by transforming Rd with Rd strA novA! novBl DNA, selecting for resistance to streptomycin, growing individual transformants, and spotting the cultures on plates containing 2.5 or 1.0 ,ug of novobiocin per ml. We obtained one transformant that grew well on the plate with 1.0 ,ug/ml but poorly on the plate with 2.5 jxglnl. The others were either resistant or sensitive to both concentrations of novobiocin. The fact that the two mutations may be separated in this way suggests that the order of the mutations relative to the strA mutation is novAl novB1 strA (Fig. 1) . Further evidence for this order is provided in the legend to Fig. 1 .
Isolation of coumermycin-and oxolinic acid-resistant mutants. Strain BC200 was mutagenized with N-methyl-N'-nitro-N-nitrosoguanidine as described previously (16) . Eight coumermycin-resistant mutants were obtained (strains JKS33 through JKS40), made into crude lysates (2) , and used to transform other strains to coumermycin resistance. One oxor mutant (JKS42) was isolated, and the mutation similarly was transferred to other strains.
Construction of H. influenzae strains containing multiple markers. Plasmids were transformed into strains as indicated after all the other desired markers were present, with selection for the plasmid marker (resistance to 5 ,ug of ampicillin or 4 ,ug of chloramphenicol per ml). Complex strains without plasmids were also constructed by transformation. Whenever there was a possibility of elimination of one of the markers by recombination during strain construction, a number of different isolates was made, and all isolates were tested for growth in the various antibiotics to make sure that none of the markers had been lost.
Construction of strain WLA5. The wild-type strain Rd, which was resistant to 1 mg of streptomycin per ml (strA mutation), was made resistant to 100 ,ug of rifampin per ml by growth in increasing amounts of rifampin and subsequently was made resistant to 25 pug of novobiocin per ml by the same method.
Plasmid preparations. H. influenzae crude cleared lysates or purified plasmid preparations were made as described previously (11) . E. coli cleared lysates were made with 6 ml of cells grown in the presence of antibiotic (50 ,iu of ampicillin or 30 ,ug of chloramphenicol per ml), centrifuged, and suspended in 33 mM Tris hydrochloride (pH 8) with 0.15 M NaCl, 64 ,ug of lysozyme per ml, and 0.04 M EDTA, followed by 2 min at 37°C with 0.7% sodium dodecyl sulfate and then overnight at 4°C with 0.8 M NaCl before a 30-min centrifugation at 15,000 rpm in a Sorvall RC-5B centrifuge. The supernatant was used for transformation.
Isolation of plasmids containing only one novobiocin resistance marker. Isolation of pNovAl was as follows. Strain JKS2 (Rd novAl) was transformed by pNovl DNA (carrying novAl and novBI, together conferring resistance to 25 ,ug of novobiocin per ml) and selected for ampicillin resistance, and transformants were obtained that grew on 2.5 but not 25 ,ug of novobiocin per ml. These proved to contain plasmids which transformed novobiocin-sensitive recipients to 2.5 but not 25 ,ug/ml, and they were not able to transform JKS2 (Rd novAl) cells to resistance to 25 ,ug/ml.
Isolation of pNovBl was as follows. Strain JKS4 (Rd novBl) was transformed similarly by pNovl DNA with selection for ampicillin resistance, and transformants were obtained that would not grow on 25 ,ug of novobiocin per ml. These proved to contain plasmids which transformed novobiocin-sensitive recipients to resistance at 1 ,ug/ml (novBl) and, in addition, could transform strain JKS2 (Rd novAl) to resistance to novobiocin at 25 ,ug/ml (novAl novBI, strain JKS5).
Measprement of outgrowth of plasmid-free cells from a culture and curing strains of plasmids. Variants of plasmidbearing strains that had lost the plasmid were obtained by individually testing surface colonies on plates with and without the relevant antibiotic. This was simple in the case of most Rd strains, which readily lose plasmids coding for gyrase when the cells are grown on the surface of agar, but very time-consuming for BC200 strains, which are difficult to cure (19) . Recombination of plasmids. Measurement of gene transfer from chromosomes to plasmids was as described previously (19) . (9) . The position of stvA (streptovaricin resistance) was provided by John W. Bendler (personal communication). The rifA locus and the relative positions of novA and novB were from our own data. The orientation of couA and novC relative to novA and novB is not known. Evidence for the ordering of novA and novB relative to strA was obtained in previous experiments by transforming a wild-type strain to streptomycin resistance with DNA that had been partially broken down and contained all three markers. Among the cotransformants to novobiocin resistance, one-fifth were novB without novA. The others were novA novB.
as described previously (19) . Cells were broken in a French pressure cell, cell debris was eliminated by low-speed centrifugation, and some of the proteins, including gyrase, were precipitated with polymin P. Fluorescence from ethidium bromide-stained gels was measured with a film scanner (23) to obtain quantitative data on the amount of conversion of relaxed to supercoiled DNA.
Growth curves. Growth in various amounts of antibiotics was monitored as the optical density at 675 nm in a Bausch and Lomb Spectronic 20. Strains to be compared were all grown at the same time, usually with three different concentrations of an antibiotic, and readings were taken at about 0.5-h intervals over a period of 4 h or more.
UV irradiation of DNA. A germicidal lamp was used for irradiation, which was performed as described previously (16) . RESULTS Nalidixic acid and oxolinic acid mutants. Because there is evidence that nalidixic acid-and oxolinic acid-resistant mutants of E. coli contain gyrase resistant to these antibiotics (22) and that these mutations code for alterations of the gyrase A subunit, it was of interest to determine the effect of the analogous H. influenzae mutations on gyrase.
A mutant, strain JKS42 (13C200 nalA2), able to grow in 0.1 ,ug of oxolinic acid per ml, also grew in 2 ,ug of nalidixic acid per ml. Similarly, a nalidixic acid-resistant mutant, JKS41 (BC200 nalAI) was able to grow in oxolinic acid. Neither strain could grow in 0.1 p.g of coumermycin per ml or in 2.5 ,g of novobiocin per ml.
Gyrase preparations of two derivatives of strain Rd (JKS6 and JKS7) containing the nalAl or nalA2 mutations showed a supercoiling activity resistant to 100 jig of oxolinic acid per ml and sensitive to 0.3 ,ug of coumermycin per ml (data not shown). We' conclude that these mutations also code for alteration of the gyrase A subunit. On the H. influenzae map, the locus for these mutations is far from the novobiocin and coumermycin resistance loci (Fig. 1) , the latter of which was shown to code for the gyrase B subunit (see below).
Phenotypes of linked novA and novB mutations. (24) . The new mutations novA2 and novB2 also conferred resistance to 2.5 and 1 p.g of novobiocin per ml, respectively, and were tightly linked to strA (Fig. 1) .
pNovl codes for the gyrase B subunit. We wished to determine which part of the gyrase enzyme was encoded by plasmid pNovl. Because novobiocin resistance is conferred by the plasmid, it seemed likely by analogy from previous results with E. coli (12) In vitro gyrase measurements with novobiocin-resistant strains. We have shown previously that plasmids containing both the novAl and novBl mutations cause the formation of gyrase that is resistant in vitro to 1.2 ,ug of novobiocin per ml (19) . Strain JKS2, which carried only the novAl mutation, also contained gyrase resistant to 1.2 ,ug of novobiocin per ml. However, gyrase from a novBl mutant (strain JKS4) was sensitive to novobiocin, even at a concentration of 0.06 ,ug/ml. These data suggest that novBi has some regulatory functipn for gyrase, enabling the cell with both novAl and novBl mutations to be resistant to 25 ,ug of novobiocin per ml, whereas the novA1 mutation alters the structure of the gyrase B subunit to make the cell resistant to 2.5 ,ug of novobiocin per ml. However, it is also possible that novBl alters the permeability of the cells to novobiocin or causes modification of the antibiotic. We favor the first hypothesis, because the novB1 mutation increases the amount of gyrase and because of the effect of a rifampin mutation (see below).
Measurements of gyrase activity in extracts of strains JKS14, Rd(pNovl), JKS4, Rd novBl, and Rd are shown in Fig. 2 . The ratio of activities from Rd(pNovl) and Rd was about 9. These data are in accord with the qualitative assessment of activities given previously (19) .
There were very large differences in the gyrase activities of the various novobiocin-resistant strains, with the following order of decreasing activity: JKS17 [Rd(pNovl)], JKS4 (Rd novBI1), JKS5 (Rd novAl novBl), and JKS2 (Rd novAI) ( Table 2 ). There was a difference by a factor of 23 between the highest and the lowest of these strains. It is of interest that the gyrase activity of JKS4 (Rd novB)) is twice that of Rd, which is in accord with the hypothesis that novB1 is involved with regulation of the gyrase B gene. Similarly, JKS5 (Rd novA) novB)) has activity higher than JKS2 (Rd novA)) but lower than Rd. Perhaps the structural mutation novA) results in a less-efficient gyrase subunit.
Novobiocin resistance and sensitivity in WLA5. The analysis of strain WLA5 described below has provided the most important new information on mutations affecting gyrase. This strain (strA Rif' Nov9 had a surprising phenotype. Although its DNA could transform wild-type cells to resistance to 50 p.g of rifampin and 250 ,ug of streptomycin per ml, it did not transform such cells to novobiocin resistance at a level greater than 2.5 jig/ml, even though the strain itself Wild-type cells were exposed to WLA5 DNA with selection for streptomycin resistance. Strr colonies were tested for resistance to 2.5 ,ug of novobiocin per ml. A total of 29% (24 of 83) of the Strr transformants tested were resistant to this level of novobiocin; thus, it was clear that at least one Novr marker of WLA5 was linked to strA (8) . This marker was designated novA3. Transformation of wild-type cells resistant to 25 p.g of novobiocin per ml to Strr with WLA5 DNA, and screening among the transformants for sensitivity to 25 jig of novobiocin per ml, showed that 16% (25 of 153) of the Strr transformants became sensitive to 25 ,ug of novobiocin per ml. Since the novB locus is linked to strA, the elimination of resistance to 25 ,ug of novobiocin per ml is presumed to be caused by the wild-type allele of novB in WLA5.
A new mutation, novC. A derivative of WLA5, referred to as strain WLA5-1, was constructed by eliminating strA, novA3, and Rif' by transformation with unmarked DNA. There were still two properties that were different from those of strain Rd, from which WLA5 was derived.
First, although neither strain Rd nor WLA5-1 grew well in 1 ,ug of novobiocin per ml, the latter grew considerably better (Fig. 3A) . Note that although Rd took more than 10 h to double, WLA5-1 took somewhat less than 4 h. Figure 3B shows a comparison of the growth of the same two strains on an expanded scale and the same two strains transformed to rifA2, the rifampin resistance marker originally obtained from WLA5. Strain WLA5-1 which was transformed to rifA2, referred to as strain WLA5-2, grew about two times faster than strain JKS11 (Rd rifA2) in 1 ,ug of novobiocin per ml.
The second difference between WLA5-1 and Rd concerned the ability of the plasmid pNovl to be retained in culture. This plasmid is readily lost from an Rd culture when cells are plated on the surface of agar without selective pressure (19) , a phenomenon attributed to enhanced induction of defective phage and killing of Rd(pNovl) (19) . Outgrowth of plasmid-free derivatives was much less marked when WLA5-1 and WLA5-3 were used (Table 3) . Mitomycin C treatment of WLA5-1 and WLA5-3 cultures caused a subsequent drop in the optical density characteristic of defective phage production (3), however, indicating that the inducible phage was still present in these strains. The new mutation, designated novC, had a significant effect on the level of novobiocin resistance when there were other resistance markers present (Fig. 4) . The triple mutant WLA5-4 (novA) novBl novC) was constructed by transforming WLA5-1 with novAI novBl DNA from JKS5. novC enabled JKS5 (novAl novBl) to grow in a much higher concentration of novobiocin than was possible without it.
The novC mutation was obtained on a plasmid by recombination between pNovl and chromosomal novC and novA) and selection for sensitivity to 25 ,ug of novobiocin per ml. (This result indicates that there is linkage between novC and novB1.) The plasmid was then transferred to the wild-type strain Rd, and the novAl gene was eliminated by recombination, leaving a plasmid with novC as the only marker affecting novobiocin resistance. This plasmid evoked a very high level of gyrase, as measured in vitro ( Table 2 ). The presence of novC on the chromosome also resulted in a much higher level of gyrase than that of the wild-type strain. The data suggest that novC increases the amount of gyrase subunit B synthesized in the cell. Thus, the multicopy pNovC plasmid caused the highest level of activity of all the strains.
Influence of a rifampin resistance marker on gyrase. Resistance of WLA5 to 25 jig of novobiocin per ml could be eliminated by exposing the cells to wild-type H. influenzae DNA and plating nonselectively. Individual colonies were tested for novobiocin resistance, and 0.8% (4 of 520) was found to be sensitive to concentrations above 1.0 ,ug/ml. All four of these transformants grew well in 1.0 ,ug of novobiocin per ml and retained their rifampin resistance, but one lost its resistance to streptomycin. This transformant was exposed to wild-type strain Rd DNA, and 2 of 884 colonies were found to be susceptible to rifampin. These two variants both lost the ability to grow well in 1.0 ,ug of novobiocin per ml. Thus, it appears that rifampin resistance (rifA2 from WLA5) might substitute for the putative regulatory mutation novBl in conferring resistance to 25 ,ug of novobiocin per ml in a novA mutant resistant to 2.5 ,ug of novobiocin per ml. Several tests were made of this hypothesis. WLA5-1 regained its ability to grow in 1.0 ,ug of novobiocin per ml when transformed to rifampin resistance with DNA from WLA5-3.
Furthermore, strain Rd, transformed to rifampin resistance with this same DNA, was also able to grow in 1 ,ug of novobiocin per ml. This transformed strain could then be transformed at a frequency of about 1% to resistance to 25 p.g of novobiocin per ml by DNA from a novAl or novA2 strain (resistant to 2.5 p.g of novobiocin per ml).
We used three different mutations that conferred resistance to 50 ,ug of rifampin per ml and that transformed into strain Rd. One, rifA1, was obtained from a clinical strain, H11008 (6), which was made resistant to rifampin by growth in increasing amounts of the antibiotic, one (rifA2, described above) was from strain WLA5, and a third (rifA3) was from a strain of H. influenzae kindly donated by Marilyn Rogers. However, only rifA2 was able to substitute for novBl in causing high-level novobiocin resistance.
The rifampin markers were mapped (Fig. 1) , and rifAl and rifA2 were transferred to plasmids, making it possible to show that the mutations involve alterations of the B subunit of RNA polymerase (W. L. Albritton, E. Cabrera-Juarez, and J. K. Setlow, unpublished data).
The transformation data with WLA5 suggest that the resistance of this strain to 25 jig of novobiocin per ml is the result of two unlinked mutations: one, linked to strA, conferring resistance to 2.5 jig of novobiocin per ml (novA2) and the other (rifA2) conferring resistance to 1.0 ,g of novobiocin and 50 ,ug of rifampin per ml. If this hypothesis is correct, all the transformants by WLA5 DNA of wild-type cells that carried novAl and selected for rifampin resistance should also be resistant to 25 ,ug of novobiocin per ml, and all transformants selected for resistance to 25 jig of novobiocin per ml should also be rifampin resistant. However, this was not the case. Although 44 of 44 rifA2 transformants were able to grow in 25 ,ug of novobiocin per ml, only 5 of 28 selected for high-level novobiocin resistance were able to grow in rifampin. Thus, the novC mutation in WLA5 could also contribute to the high-level novobiocin resistance. Coumermycin-resistant mutants. In contrast to the situation in E. coli, in which all coumermycin-resistant mutants are also resistant to novobiocin (7, 12) , only one (couA6) of the eight coumermycin resistance mutations, when transferred into the wild-type strain, also conferred resistance to 1.0 and 2.5 ,ug of novobiocin per ml. All conferred resistance to 0.5 ,g of coumermycin per ml. The couA6 mutation apparently consists of two tightly linked mutations, since we were able to separate them by transformation with a plasmid bearing the two mutations (see below).
All eight couA mutations were closely linked to strA, as judged by couA strA cotransformation from crude lysates of cells carrying both these markers (about 40%), suggesting that the couA mutations are close to the novA and novB mutations and possibly in the same gene. Further evidence that two of the couA mutations are close to the novA novB complex was obtained by isolating plasmids carrying the couA mutations.
The idea behind the plasmid isolation was that the couA mutations might be present on a part of the chromosome homologous to the chromosomal portion of the pNovl plasmids. Thus, pNovls, carrying information for novobiocin sensitivity (19) , was used to transform BC200 containing the couA6 or couA8 mutations in the hope that the plasmid might acquire the mutation by recombination. Since such recombinant plasmids were found, albeit at a low frequency, and since they were the same size as the original pNovls, we conclude that the locus of couA mutations is on the 9-kilobase-pair chromosomal insert of pNovl (18) (Fig.  1) .
Separation of the couA and novA mutations in a couA6 strain. Although the mutations repeatedly transformed together when chromosomal DNA was used as donor, an indication that there were two different mutations in the couA6 strain came from an experiment to measure recombination between the pCouA6 plasmid and the chromosome. Ampicillin transformants of BC200 by the plasmid were picked; grown in ampicillin; and spotted on ampicillin, ampicillin plus coumermycin, and ampicillin plus 2.5 ,ug of novobiocin per ml. The recombination, measured as the loss of the markers of the chromosomal insert, coumermycin, and novobiocin resistance, with the corresponding sensitivity information acquired from the recipient chromosome (17) , was different for the two markers. Thus, only 23 of 78 of the transformants were novobiocin resistant, but 59 of 78 of the transformants were coumermycin resistant. Further evidence for two different mutations comprising the original couA6 mutation was obtained by transformation with plasmids purified from two different transformants of the original plasmid. One of the plasmids transformed wild-type cells to both novobiocin and coumermycin resistance, and the other transformed wild-type cells to coumermycin resistance alone. Thus, the latter plasmid lost the novobiocin resistance marker by recombination with the chromosome.
Evidence that couA6 and couA8 are mutations of the gyrase B subunit gene. An extract of the couA8 mutant contained gyrase resistant to 0.3 jig of coumermycin per ml, but sensitive to 1.2 ,ug of novobiocin per ml. Similarly, the coumermycin-resistant, novobiocin-sensitive transformant of the original pCouA6 plasmid showed these same properties, but the transformant resistant to both antibiotics contained gyrase resistant to both antibiotics. These data suggest that the coumermycin-resistant mutants, like the novA mutants, contain alterations in the gene for the gyrase B subunit.
Little loss of coumermycin plasmids during growth of cultures on the surface of agar. When plasmids coding for novobiocin resistance or novobiocin sensitivity are in strains such as Rd, containing the inducible defective prophage, and cells are plated on the surface, it is characteristic that there is a selective bias against cells containing the plasmids. Thus, almost all of the surviving cells of the culture do not contain plasmid because of the increased probability of defective phage induction and the consequent loss of viability in plasmid-containing cells (19) . Cells containing plasmids carrying resistance to coumermycin, however, did not show any such selective bias (Table 3) . Also included in Table 3 is comparison of the data for Rd(pNovl) and Rd(pNovls). In the strains carrying couA plasmids, the defective phage was normally inducible by mitomycin C, as judged by the drop in optical density after about 2 h of incubation in growth medium (3) . Thus, the lack of outgrowth of cells without plasmids from these strains did not result from a loss of prophage.
The recombinant plasmids pCouA6s and pCouA8s showed outgrowths similar to those of pNovl and pNovls (Table 3) . Since several coumermycin-sensitive, ampicillinresistant transformants of each plasmid were found to show the same rapid outgrowth phenomenon, it was concluded that the coumermycin resistance markers in the plasmids caused the lack of outgrowth.
Coumermycin resistance mutations and in vitro gyrase activity. Table 2 shows that the plasmids carrying couA6 and couA8 evoked high activity, whereas the same markers on the chromosome evoked activity lower than that of wild-type strain Rd. It is unlikely that the low activity found in JKS8 Effect of mismatch at the novB locus on repair of UV damage to transforming DNA and on plasniid-chromosome recombination. Day and Rupert (4, 5) have shown that mismatch at the novB (formerly Nb3) locus affects both the frequency of transformation and the UV resistance of transforming DNA carrying novA. Thus, if the chromosome carries novBl and the transforming DNA is wild type at this locus, or vice versa, there is little or no repair of UVdamaged transforming DNA, even in repair-proficient cells, and the efficiency of transformation of novA is about half that obtained when the novB marker is matched in the transforming DNA and chromosome. Figure 5 shows that our novBl marker in strain Rd (JKS4) behaved similarly to the Nb3 marker of Day and Rupert, in that when UVirradiated DNA carrying the novBl and novAl mutations was assayed on strain Rd for resistance to 25 ,ug of novobiocin per ml, the UV sensitivity was about seven times greater than when the same transforming DNA was assayed on strain JKS4 (Rd novB1), the latter being matched with the transforming DNA at the novB locus. Furthermore, assay of another marker on the same irradiated DNA, namely nalAl, conferring resistance to nalidixic acid, did not show any difference in UV sensitivity whether or not the novBl mutation was present in the recipient (data not shown). Day and Rupert obtained similar results with DNA carrying an erythromycin resistance marker (4 effect seen in Fig. 5 is apparently limited to the novA and novB markers in the transforming DNA.
The results in the unmatched situation were similar when the recipient was strain BC200 (Fig. 5) , although in two experiments the DNA appeared to be slightly more resistant than in strain Rd. We presume that a small fraction of the Rd transformants were induced for defective phage, since this type of induction and killing has been observed previously (14) . Figure 5 also shows that when the BC200 recipient carried a different novB mutation, novB2 (JKS31), the protective effect was not nearly so great as with the JKS4 (Rd novBI) recipient. Thus, novB2 is apparently only partly analogous to novBl. The UV sensitivity of novAl novBI-transforming DNA was not decreased when novC was in the recipient chromosome, indicating that novC is apparently not an allele of novBl.
The differences between the apparent UV sensitivity of the DNA among recipient strains were not the result of donor strain differences, since DNA from a BC200 derivative carrying the novAl novBl mutations (JKS32) gave the same result as DNA from the Rd derivative JKS5 (data not shown).
Mismatch at the novB locus favored recombination between plasmid and chromosome that resulted in acquisition of chromosome genetic information by the plasmid. This effect was the opposite of that on transformation and UV repair. Table 4 shows that the chromosome to plasmid recombination was about twice as great when there was a mismatch at novB. The reason for this could be trivial, in that the match situation may favor integration of a portion of plasmid DNA into the recipient chromosome, eliminating the plasmid (18) . Mismatch would then favor establishment of the plasmid and, consequently, greater genetic transfer from chromosome to plasmid.
Day and Rupert (5) have noted that integration of transforming DNA into the chromosome can be slower in the case of mismatch at the novB locus. The UV sensitivity of DNA with such a mismatch may then reflect this slower integration. We are in the process of sequencing the novBl locus in pNovBl and pNovls (the latter with the wild-type gene) to determine whether this mutation involves significant nonhomology with respect to the wild type.
cis or trans activity of nonstructural gyrase mutations. Since the rifampin mutations code for an altered gene product, we would expect them to act in trans. Evidence that novBl functions only in cis was obtained with the rec-J mutant (JKS14) since its use eliminated the possibility of recombination between plasmid and chromosome during strain construction. The following strains were constructed: rec-J novAl(pNovBl), rec-J novBl(pNovAl), rec-J novAl novBl(pNovAl), and rec-J novA) novBl(pNovBl). Since only the last two were able to grow in liquid culture containing 25 ,ug of novobiocin per ml, and rec-J(pNovAlNovBl) does so as well (18) , it was concluded that novAl and novBl must be on the same molecule to obtain that level of resistance to the antibiotic.
The fact that novC can raise the resistance to novobiocin in a strain containing the novAl novBl mutations when novC is either on the chromosome or in a plasmid (Table 5 , experiments 17, 19, and 20) is evidence that novC can act in trans. Additional evidence concerns the property of novC that prevents outgrowth of cells lacking the plasmid coding for the gyrase B subunit, causing the plasmid to be retained when cells are grown on an agar surface. WLA5-1 (strA+ novA2+ rifA2+ novC) was transformed with pNovl and selected for ampicillin resistance. There was little loss of the plasmid when the cells were grown on the surface of agar (Table 3) . A cleared lysate was made of the transformed culture, and 10 ampicillin-resistant transformants of strain Rd were isolated after exposure to the lysate. The individual transformants were grown on the surface of agar, and 26 to 52 colonies of each were tested for loss of plasmid. From 80 to 100% lost the plasmid. Therefore, the original variant WLA5-1(pNovl) culture must have had the novC mutation in the chromosome but not on the plasmid, and thus the mutation must have functioned in trans.
Interrelationships of mutations affecting gyrase as shown by growth in antibiotics. Table 5 shows growth of strains with and without combinations of the mutations in various amounts of novobiocin or coumermycin. Without mutations, wild-type strains Rd and BC200 and the recombinationdefective JKS14 rec-J strain did not grow in the lowest concentrations of the antibiotics used (Table 5 , experiments 1 to 3). When novBl was on a multicopy plasmid the resistance to the antibiotic increased, presumably because there was more of the gyrase B subunit made (Table 5 , experiments 4 to 7). (It has been shown in E. coli [21] that novobiocin exerts its inhibitory effects by blocking the binding of ATP to subunit B, but the subunit from novobiocin-resistant cells is not affected.) Thus, when there is more of the B subunit made, more novobiocin would be expected to be required to block gyrase action. Multiple copies of novA) caused resistance to a higher level of novobiocin than when the marker was on the chromosome (Table 5 , experiments 8 to 11).
It is notable that the novBl mutation alone (Table 5 , experiment 4) produced an increase in the ability to grow in novobiocin, but not in coumermycin, although multiple copies of pNovls ( (Table 5 , experiments 5 to 7). These facts could be reconciled by assuming that novobiocin inhibits not only gyrase activity but also transcription of the gyrase B gene and that the novBI mutation permits a normal level of transcription to take place in the presence of novobiocin.
The novC mutation alone in the chromosome did not cause resistance to either antibiotic under the conditions indicated for experiment 12 in Table 5 . However, the plasmid with or without novC caused some resistance to coumermycin (Table 5, experiments 13 to 15). The mutation also caused an increase in novobiocin resistance in novAl novBl cells (Table 5 , experiments 16 to 18), as seen in Fig. 4 . The plasmid containing the novC mutation also raised the resistance of the cells with novAl novBl in the chromosome, and
